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AZT = 3¢-azido-3¢-deoxythymidine; FNA = fine-needle aspirate; hTERT = human telomerase reverse transcriptase catalytic subunit; hTR = human
telomerase RNA component; PCR = polymerase chain reaction; TRAP = telomeric repeat amplification protocol.
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Overview of telomeres and the use of
telomerase to compensate for telomere loss
Human chromosomes contain repeated TTAGGG DNA
sequences at their ends (telomeres) that provide genomic
stability (protect the ends from being recognized as DNA
breaks needing repair) and a source of expendable DNA
(a solution to the inability of the replication machinery to
copy the extreme ends of chromosomes: the end replica-
tion problem) (see [1] for a review). A significant amount
of truncation can occur during DNA replication without
causing deleterious effects. Human telomeres progres-
sively shorten with ongoing cell division until they reach a
critical length that induces replicative senescence [2].
Recent research has led to increased knowledge of the
structure and function of telomeres. Telomeres end in G-
rich single-stranded 3¢ overhangs, and can form a lariat
structure called a t-loop. Telomere binding proteins such
as TRF1 and TRF2 are thought to protect against nucle-
ases and prevent DNA recombination or end joining [1].
Recent research has shown an increasing connection
between DNA damage repair proteins (eg Mre11/Rad50/
Nbs1, Ku, etc) and telomere biology in mammals. Double-
strand break recognition and repair factors associated
with the BRCA1-associated genome surveillance complex
have, for instance, been linked to telomeres and telomere
binding proteins [3]. BRCA1 or BRCA2 might also play a
role in telomere structure and function.
Although other mechanisms to maintain telomere stability
are possible, the mechanism for lengthening telomeres in
humans is almost always by the reactivation or upregula-
tion of telomerase [4]. Human telomerase is a protein
complex consisting of a human telomerase reverse trans-
criptase catalytic subunit (hTERT) that uses the human
telomerase RNA component (hTR) of the complex as a
template for adding TTAGGG repeats to the end of the
chromosome [5–7]. Telomerase is only expressed in a
small number of proliferating cell types, such as germ line
and somatic stem cells. Most normal human cells lack
telomerase activity and their telomeres shorten with each
cell division, until they enter replicative senescence. Cells
that lose critical cell-cycle checkpoint functions escape
this initial growth arrest and divide until they enter crisis
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Current therapies for breast cancer include treatments that are toxic and often result in drug resistance.
Telomerase, a cellular reverse transcriptase that maintains the ends of chromosomes (telomeres), is
activated in the vast majority of breast cancers (over 90% of breast carcinomas) but not in normal
adjacent tissues. Telomerase is thus an attractive target for both diagnosis and therapy because of its
distinct pattern of expression. We address the use of telomerase in the diagnostics of breast pathology,
as well as the use of telomerase inhibitors in the treatment and prevention of breast cancer.
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when chromosome end fusions and apoptosis occur.
Cells remain in this crisis period unless a rare cell acquires
a mechanism, such as telomerase expression, that can
lengthen telomeres. As cells continue to proliferate, the
maintenance of telomeres involves a collection of factors
including telomere binding and associated proteins, the
telomerase ribonucleoprotein complex and, potentially,
DNA damage repair proteins. A rare cell that can maintain
telomeres is then able to grow continuously (ie becomes
immortal) and this is generally believed to be a critical step
towards cancer progression [8].
Telomerase as a diagnostic target: incidence
of telomerase in breast cancer
The development of the telomeric repeat amplification
protocol (TRAP) assay led to an expansion in the ability to
detect telomerase activity in human cancer cells [9]. This
sensitive polymerase chain reaction (PCR)-based assay
can detect as few as 1 to 10 positive cells or 0.01% in a
mixed population. Although preliminary data showed 88%
of all stages of breast carcinoma having positive TRAP
[9], closer investigation and careful handling of initially
negative samples revealed the value may be closer to
95% [10]. As reviewed by Shay and Bacchetti, 75% of
breast carcinoma in situ lesions, 88% of ductal and
lobular carcinomas, 5% of adjacent tissues, and none of
the normal tissues were TRAP-positive [9]. Yashima et al
detected a progressive increase in the mean telomerase
levels with the severity of histopathological change: 14%
in benign breast diseases, 92% in carcinoma in situ
lesions, and 94% in invasive breast cancers [11]. Expres-
sion of the hTERT mRNA can also be detected using
real-time quantitative reverse transcriptase-PCR, and this
assay revealed a statistical link between hTERT mRNA
levels and the aggressiveness of breast tumors [12].
Both this semi-automated assay and the TRAP assay
provide suitable methods for breast cancer diagnosis, but
should be used in conjunction with other diagnostic tools
to rule out false results.
Detection of telomerase activity in preoperative speci-
mens, such as in fine-needle aspirates (FNAs), may
improve diagnostic accuracy [13,14]. FNA cytology is
known to be accurate, cost effective and have minimal
risk [14]; however, difficulties still occasionally occur
using cytology alone. Two groups separately compared
the diagnostic utility of telomerase assays of FNAs with
cytology preparations [13,14]. Poremba et al showed
that 92% of FNAs from breast cancer patients were
telomerase-positive, 94% of FNAs from patients with
benign breast lesions were telomerase-negative (the
positive cases were all fibroadenomas), and there was a
strong correlation between TRAP and histologic diagno-
sis of atypia [13]. Hiyama et al observed that all atypical
or intermediate cases with detectable telomerase activity
in the FNAs were found to be carcinomas after surgery
[14]. Furthermore, six out of seven tumors without telom-
erase activity were diagnosed as benign, while one half
of the cases with detectable telomerase activity, initially
designated by cytology as benign, were subsequently
diagnosed as cancer. Detecting telomerase activity in
FNAs is thus equivalent, if not better, than detection by
cytology [14], and can be used in conjunction with other
diagnostic tests. Finally, tumor-derived telomerase RNA
found in the serum of breast cancer patients may have
implications in diagnosis and in follow-up monitoring
studies [15].
Telomerase activity and prognosis in breast
cancer
With the increasing number of breast cancers detected
by screening procedures, a marker is needed to stratify
the risk of subsequent invasive cancer. Hoos et al found a
significant correlation between telomerase activity and
tumor size, lymph node status, and stage [16]. A signifi-
cant association between telomerase-positive infiltrating
breast carcinomas and lymphovascular invasion, a funda-
mental step in breast cancer metastasis and a predictor
of survival, has also been observed, making telomerase a
useful prognostic marker [17]. Clark et al reported, in a
prognostic study involving 398 patients with lymph node-
positive breast cancer, that increased telomerase activity
was associated with decreased disease-free survival
[18]. High telomerase activity in breast cancer is more-
over associated with genetic aberrations in 3q (gain), 8q
(gain), and 17p (deletion) [19]. These aberrations are
common in breast cancers and involve the hTR (on 3q),
c-myc (on 8q), and p53 (on 17p) genes, all of which have
been associated with telomerase regulation [19]. Under-
standing the link between telomerase activity and genetic
changes associated with breast cancer remain an impor-
tant area of research today.
Telomerase inhibition as an anticancer
approach
The average telomere length in breast cancer cells is
usually well below that of normal cells. This difference in
telomere length coupled with the more rapid rate of cell
division in cancer cells makes the inhibition of telomerase
an attractive potential breast cancer therapeutic target.
Treatment with telomerase inhibitors may not have the
toxicity found with other chemotherapeutic agents since
telomerase is absent in most somatic cells (Fig. 1). While
normal, proliferating telomerase-positive stem cells may
also initially be affected, their telomeres are well above
the critically short length that induces a DNA
damage/growth arrest mechanism. Furthermore, most
stem cells are quiescent, and telomere shortening nor-
mally only occurs with cell division. Since most breast
cancer cells have very short telomeres, treatment with
telomerase inhibitors should lead to growth arrest and
cell death.Breast Cancer Research    Vol 3 No 3 Shea Herbert et al
Advances in development of telomerase
inhibitors
The telomerase protein complex allows for multiple sites
for inhibition. Recent research includes targeting the RNA
component of the telomerase (antisense oligonucleotides,
hammerhead ribozymes), inhibition of the catalytic subunit
(dominant negative mutant hTERT, reverse transcriptase
inhibitors), immunotherapy, and small molecule inhibitors
(reviewed in [20]). It is important in most approaches to
confirm that telomerase inhibitors are acting specifically in
a telomere-dependent mechanism. First, telomerase
inhibitors should almost always lack immediate toxicity to
the cell; they should reduce telomerase activity without ini-
tially compromising cellular proliferation. Second, without
telomerase activity, telomeres should progressively
shorten with each cell division. Cells should ultimately die
or undergo growth arrest and the time required should be
related to initial telomere length. Over 100 manuscripts
have been published on telomerase inhibitors but only a
small number meet the presented criteria [20], and fewer
still have been tested in breast cancer cells.
Antisense oligonucleotides, dominant negative mutant
hTERT and reverse transcriptase inhibitors have been
studied in breast cancer [20–22]. The most widely used
reverse transcriptase inhibitor is 3¢-azido-3¢-deoxythymidine
(AZT) (reviewed in [20]). Melana et al observed that AZT
inhibited the growth of breast cancer cells and telomerase
activity at lower doses than in normal breast cells [21].
Multani  et al, however, showed that AZT reduced the telom-
eric signals, as detected by fluorescence in situ hybridiza-
tion, in human MCF-7 breast carcinoma cells within 72 h
[22], a time too short to be explained by the inhibition of
telomerase and progressive telomere shortening. The
effects of AZT, while effective in inhibiting breast cancer cell
growth in these studies, may not be due to a specific telom-
ere-dependent mechanism, and telomerase inhibition may
just be a side effect [20]. Whereas further research is
needed to prove the specificity of AZT, studies using both
antisense oligonucleotides, such as 2¢-O-methyl RNA
directed against the hTR template region, and dominant
negative mutant hTERT have been shown to be effective
specific telomerase inhibitors in immortalized breast epithe-
lial and breast carcinoma cells in vitro (reviewed in [20]).
Standard chemopreventive agents have also been investi-
gated for a possible role in telomerase inhibition and
control of breast cancer. Retinoic acid and tamoxifen have
Figure 1
Effects of telomerase inhibitors in breast cancer therapy based on reviews by Krupp et al [1] and White et al [20]. Normal breast tissues do not
have telomerase activity and their telomeres progressively shorten with each cell division. When telomeres become short, cells undergo growth
arrest. In rare circumstances, telomerase may be activated and a cell can become immortal, leading to accumulations of mutations and cancer.
Inhibition of telomerase would lead to progressive shortening of telomeres. While normal, telomerase-competent proliferating cells, such as germ
and stem cells, would be affected, their telomeres are well above the critically short length to induce a DNA damage/growth arrest mechanism.
Since most breast cancer cells exhibit telomere lengths close to the critically short limit, treatment with telomerase inhibitors would lead to growth
arrest and cell death. With the removal of inhibitors, telomerase would be active and telomere lengths might return to their original size.already been shown to inhibit telomerase activity in breast
cancer cells [23,24], probably as a secondary conse-
quence of inhibition of proliferation. While these agents
are known for their antiproliferative effects, not much is
known on their effects on immortalization, a critical step
towards breast cancer progression [8]. We have recently
investigated the possibility of using these agents or spe-
cific telomerase inhibitors to prevent cellular immortaliza-
tion as a breast cancer chemoprevention strategy. We
found that long-term treatment of precrisis breast epithelial
cells with nontoxic doses of either chemopreventive or
antitelomerase agents significantly lowered the frequency
of spontaneous immortalization [25]. Our studies provide
a new model for the screening of novel chemopreventive
agents that target cellular immortalization.
Conclusion
Telomerase is an attractive target for diagnosis and
therapy since it is expressed in over 90% of breast cancer
cells, while it is not expressed in most normal cells.
Whereas most of the progress on the role of telomerase in
breast cancer has been in diagnostics, research into
telomerase inhibitors is increasing. Inhibition of telomerase
in vitro leads to progressive telomere shortening, eventu-
ally resulting in growth arrest or cell death due to the criti-
cally short telomeres inducing a DNA damage response.
Breast cancer cells with already short telomeres would be
most affected by telomerase inhibitors, whereas normal
stem cells with longer telomeres would be relatively resis-
tant. The effects of telomerase inhibitors would depend on
initial telomere length and rate of cell division, and it may
take weeks to months to see changes in tumor size. Com-
bining telomerase inhibitors with current therapies to
reduce tumor burden may thus provide a better regimen to
target breast cancer and prevent recurrence.
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